Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRAPE: Tamivarotene + Nivolumab + GC in Urothelial Carcinoma
NCT06983210Phase 2Recruiting
- Sponsor
- Nagoya University
- Start
- May 2025
- Primary completion
- Mar 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of tamibarotene in urothelial carcinoma (UC), sponsored by Nagoya University. Started May 2025; status: recruiting.
02
Drugs
tamibarotene
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06983210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06983210.